Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Anthropic IPO Marketing Expected to Start in Mid-October 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Xiaomi Shares Jump on Europe EV Expansion Plan 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Milei Threatens Falkland Oil Firms With Sanctions 
Add as a preferred source on Google
MENLO PARK, Calif., Feb. 26, 2018 -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer of Adverum, will present at upcoming investor conferences in March.
| Event: | Raymond James 39th Annual Institutional Investors Conference | ||||
| Date: | March 5, 2018 | ||||
| Time: | 9:15 – 9:45 a.m. ET | ||||
| Location: | Orlando, FL | ||||
| Event: | Cowen and Company 38th Annual Health Care Conference | ||||
| Date: | March 12, 2018 | ||||
| Time: | 1:30 – 2:00 p.m. ET | ||||
| Location: | Boston, MA | ||||
| |
A live and replay audio webcast of these presentations will be available from Adverum’s website at http://investors.adverum.com.
About Adverum Biotechnologies, Inc.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Adverum Contact:
Leone Patterson
Chief Financial Officer
650-665-7222
[email protected]
